Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum.
about
Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expressionEvidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteriesActivation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscleIncreased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertensionPivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Phosphodiesterase 5 inhibitors: current status and potential applications.NO as a signalling molecule in the nervous system.ABCD of the phosphodiesterase family: interaction and differential activity in COPDThe role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesPhosphodiesterase type 5 and high altitude pulmonary hypertension.Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.Emerging oral drugs for erectile dysfunction.Tissue expression, distribution, and regulation of PDE5.Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction.Physiological regulation of penile arteries and veins.Evolutionary conservation of alternative splicing in chicken.Lack of direct androgen regulation of PDE5 expression.Immunohistochemical localisation of PDE5 in rat lung during pre- and postnatal developmentPhosphodiesterase-5 expression and function in the lower urinary tract: a critical review.Clinical and molecular genetics of the phosphodiesterases (PDEs).Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.Direct androgen regulation of PDE5 gene or the lack thereof.Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases.Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ionsThe phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects.Isolation of two isoforms of phosphodiesterase 5 from rat penis.Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5).Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen.Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.Regulation of phosphodiesterase 5 expression and activity in human pregnant and non-pregnant myometrial cells by human chorionic gonadotropin.Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase.Cyclic nucleotide signalling in malaria parasites.
P2860
Q22254649-44CC2DA7-A157-4845-B55D-6DD703570B0DQ28345798-F3197C0E-014B-4396-AA9F-50FA796DA72EQ28363328-ED0E67A3-D92C-4962-9F7F-69E14A37827EQ28567348-B466A6E6-A874-4127-9D98-089907944BFDQ33552229-FA0D6256-A379-40D9-8DD6-0CDDE0FB9483Q34147460-B663423D-8B2C-41F0-BE92-EF565A0E3A30Q34551365-32748DAC-BDEF-49CB-B55F-1A4BBC233BC6Q34961511-2343298F-9124-4B4F-B0A2-7C6266C4E401Q35156618-35E39BFF-8077-4F66-89AF-0ED4D9290E20Q35537900-0C58A29D-FA26-49C0-B1E7-2D0DF3F0A349Q35765882-2A7677E0-1A3E-49AA-A518-4EDA0D34066CQ35779307-2717C2EE-3FBC-4FB2-8332-E9576CFB4897Q35821255-5B2128C2-2CEF-4C92-B494-07B3C4CAA2C9Q36293532-0D2A3E9B-75F1-4A81-ACFF-B3B8609F94C7Q36334968-708761A9-D87D-4E19-BFE2-A29642C9E7BEQ36395193-5313222E-57F9-462B-94FC-3AC304169F88Q36572591-0975B1DC-88F8-460D-A39A-DC763D830DB1Q36885422-333776EB-6847-4248-8ADB-F2FE12ABB4AAQ37053510-12113C7C-D2D4-46CD-9B9B-FC99D009EF61Q37187077-900B4951-E816-4281-BBF7-CA7BCD7E6677Q37314620-18485BC3-A2B0-4028-AAEB-881DADB80513Q37340520-10EA96D5-EEE1-4CB0-8C5C-C0D79C3326DAQ37657841-42AF1740-56A0-4298-AA1D-27F87A63F4BAQ37960885-A0745A21-E3C5-4C58-A2C7-A29312D7B140Q38088930-AE71D91A-B471-44FF-8E85-4A92490CC63DQ38205932-F47B0AFA-1E90-451A-87DC-2724422B4F32Q39141728-DAD891A7-B84E-49A6-9232-CFE549B4E771Q42650059-1B5A1C1E-44D3-4F5F-9EC9-36BBCDA79BD2Q44129739-4B19BD0F-FA0D-4A19-B03F-89D7145A0B39Q44467347-74E288C9-4A5C-4D16-BA4C-9513A43F0646Q44529978-5316E32C-8C72-4D0A-8D06-D48CBCC8980BQ44919822-BC741A6A-EA82-43C9-9EDB-FE47EFD2E7C1Q46140666-EA60202D-8166-469A-B1C9-56D1818450A3Q46427835-956764A0-68A5-48A8-9821-A3A95755A2C5Q46833989-C1EEB7F3-06DA-4804-943A-3AEBA543802DQ46957389-F4B5B758-72B9-4DB5-BD8C-9F8ABFDFB302Q47097185-193EE34D-4B98-448E-98EE-FBDB00BEB947
P2860
Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Expression of three isoforms o ...... 5) in human penile cavernosum.
@en
type
label
Expression of three isoforms o ...... 5) in human penile cavernosum.
@en
prefLabel
Expression of three isoforms o ...... 5) in human penile cavernosum.
@en
P2093
P356
P1476
Expression of three isoforms o ...... 5) in human penile cavernosum.
@en
P2093
P304
P356
10.1006/BBRC.2000.2187
P577
2000-02-01T00:00:00Z